
## Péter HollÃ<sup>3</sup>

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2751482/publications.pdf Version: 2024-02-01



ΡΑΘτερ Ηοιι Α3

#	Article	IF	CITATIONS
1	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. European Journal of Health Economics, 2014, 15, 111-119.	2.8	60
2	Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Quality of Life Research, 2017, 26, 3409-3419.	3.1	51
3	Is the DLQI appropriate for medical decision-making in psoriasis patients?. Archives of Dermatological Research, 2018, 310, 47-55.	1.9	24
4	Changing Trends in Melanoma Incidence and Decreasing Melanoma Mortality in Hungary Between 2011 and 2019: A Nationwide Epidemiological Study. Frontiers in Oncology, 2020, 10, 612459.	2.8	14
5	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	4.1	12
6	A Rasch model analysis of two interpretations of â€~not relevant' responses on the Dermatology Life Quality Index (DLQI). Quality of Life Research, 2021, 30, 2375-2386.	3.1	10
7	Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients. Life, 2021, 11, 919.	2.4	9
8	Seroconversion after <scp>antiâ€SARSâ€CoV</scp> â€2 <scp>mRNA</scp> vaccinations among moderateâ€toâ€severe psoriatic patients receiving systemic biologicals—Prospective observational cohort study. Dermatologic Therapy, 2022, 35, e15408.	1.7	7
9	The prevalence of ADH1B and OPRM1 alleles predisposing for alcohol consumption are increased in the Hungarian psoriasis population. Archives of Dermatological Research, 2019, 311, 435-442.	1.9	6
10	Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters' Levels, but Has No Effect on Body Composition Parameters. Life, 2021, 11, 535.	2.4	6
11	Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice. Postepy Dermatologii I Alergologii, 2019, 36, 589-594.	0.9	5
12	Novel antiâ€inflammatory therapies to reduce cardiovascular burden of psoriasis. Dermatologic Therapy, 2021, 34, e14721.	1.7	4
13	Multispectral Imaging Algorithm Predicts Breslow Thickness of Melanoma. Journal of Clinical Medicine, 2022, 11, 189.	2.4	4
14	Preservative Contact Hypersensitivity among Adult Atopic Dermatitis Patients. Life, 2022, 12, 715.	2.4	3
15	Improving Quality Indicator of Melanoma Management – Change of Melanoma Mortality-to-Incidence Rate Ratio Based on a Hungarian Nationwide Retrospective Study. Frontiers in Oncology, 2021, 11, 745550	2.8	2